Replies to post #39309 on Cel Sci Corporation (CVM)

[conix]

I tend to agree that if these results show 14% survival improvement in non-chemo patients, it suggests that the SOC could become non-chemo therapy with MultiKine.

The volatility today is, imo, the triumphant shorts covering and playing the bounce to short again.

Geert has a huge incentive to schedule a Conference Call to address the concerns.

Adam F, say what you will, but to date his stance has helped the shorts--because he was right.

[greenJack]

Exact. Multikine instead of Chemo, seems the market still has to absorb the results of the Ph3.

[exwannabe]

Cherry pick a subgroup out of the dozens that are written into a protocol/SAP and one is likely to work by pure luck of the draw. It does not mean the agent worked.

Here is the elephant in china shop in the PR. With (supposedly) 50% of the trial having done this well, then the overall trial should do fairly well even if Multikine did not work in another patients.

But they never reported the overall data. And that is the key to understanding when companies spin subgroups.

[W_W]

On top of that, multikine's way to enhance the immune system is a correct way to do, not anything as long as enhancing immune system will help treating cancer. This shows how significant it is.
Why not use it on other cancers since it has not side effects.